Finance entity
Every one of those 1 sits in a single category, regulation. Of the tracked stories, 1 of 1 also mention Food and Drug Administration, the most common co-covered peer. At 8, the average consequence score sits above the same-window beat average of 6.2.
Last mentioned: Mar 16, 2026
Entity pulse
Coverage balance Negative coverage leads. Negative coverage exceeds positive coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, regulation. Of the tracked stories, 1 of 1 also mention Food and Drug Administration, the most common co-covered peer. At 8, the average consequence score sits above the same-window beat average of 6.2. They are less corroborated than the beat average, carrying 2 original sources each against 2.6 for the same window. We currently track 1 Finance story that mention Vinay Prasad, all published on March 16, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 107 Finance stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Vinay Prasad. Shared-story counts are live from our verified record — not editorial picks.
Industry Warning
Editorials warn that erratic FDA behavior is a threat to biotech innovation.
Refusal to File
FDA regulator Vinay Prasad refuses to review Moderna's flu vaccine application.
Regulatory Alignment
FDA officials reportedly signal support for Moderna's trial data workaround.
Grant Rescission
The federal government rescinds hundreds of millions in mRNA research funding.
Peak Valuation
Moderna reaches a market capitalization of $200 billion during the pandemic height.
Moderna Inc. faces a critical juncture as the FDA's increasingly erratic regulatory stance and shifting White House sentiment jeopardize the future of mRNA technology. A rare refusal to review the company's flu vaccine data highlights a growing rift between the agency and the industry it oversees, threatening the predictability required for biotech investment.
Vinay Prasad is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
